Herein, identification of the predictive role of PIK3CA mutation status on the clinical outcomes of PI3K inhibitors should be of great priority to benefit the diagnosis and prognosis for patients with HR+ breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.